Review of third-and fourth-generation fluoroquinolones in ophthalmology: In-vitro and in-vivo efficacy

Advances in Therapy

Volumn 25, Issue 10, 2008, Pages 979-994

  Scoper, Stephen V ^a  

^a Virginia Eye Consultants   (United States)

Author keywords

Antibiotic susceptibility; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Keratitis; Levofloxacin; Moxifloxacin; Penetration; Potency

Indexed keywords

ANTIINFECTIVE AGENT; GATIFLOXACIN; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

DRUG EFFECT; ENDOPHTHALMITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KERATITIS; MICROBIOLOGICAL EXAMINATION; OPHTHALMOLOGY; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; ENDOPHTHALMITIS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; KERATITIS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; OPHTHALMOLOGY; QUINOLINES;

EID: 61749103182     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0107-x     Document Type: Review

References (49)

1. Ciloxan® [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; 2006.
2. Ocuflox® [package insert]. Irvine, CA: Allergan, Inc.; 2002.
3. Olson RJ. Reducing the risk of postoperative endophthalmitis. Surv Ophthalmol. 2004;49(suppl. 2):55-61.
4. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004;49(suppl. 2):73-78.
5. Garcia-Rodriguez JA, Gomez Garcia AC. The microbiology of moxifloxacin. Drugs Today (Barc). 2000;36:215-227. (Pubitemid 30176462)
6. Just PM. Overview of the fluoroquinolone antibiotics. Pharmacotherapy. 1993;13:4-17.
7. Chaudhry NA, Flynn HW Jr., Murray TG, Tabandeh H, Mello MO Jr., Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 1999;128:509-510. (Pubitemid 29479329)
8. Goldstein MH, Kowalski RP, Gordon J. Emerging fluoroquinolones resistance in bacterial keratitis: a 5-year review. Ophthalmology. 1999;106:1313-1318. (Pubitemid 30191477)
9. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497-1502.
10. Watanabe K, Numata-Watanabe K, Hayasaka S. Methicillin-resistant staphylococci and ofloxacin-resistant bacteria from clinically healthy conjunctivas. Ophthalmic Res. 2001;33:136-139. (Pubitemid 32424537)
11. Quixin® [package insert]. Jacksonville, FL: Vistakon Pharmaceuticals, Inc.; 2006.
12. Healy DP, Holland EJ, Nordlund ML, et al. Concentrations of levofloxacin, ofloxacin, and ciprofloxacin in human corneal stromal tissue and aqueous humor after topical administration. Cornea. 2004;23:255-263. (Pubitemid 38401902)
13. Koch HR, Kulus SC, Roessler M, Ropo A, Geldsetzer K. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. J Cataract Refract Surg. 2005;31:1377-1385. (Pubitemid 41583354)
14. Puustjarvi T, Terasvirta M, Nurmenniemi P, Lokkila J, Uusitalo H. Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the noninflamed human eye. Graefes Arch Clin Exp Ophthalmol. 2006;244:1633-1637. (Pubitemid 44830823)
15. Drugeon HB, Juvin ME, Bryskier A. Relative potential for selection of fluoroquinoloneresistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin. J Antimicrob Chemother. 1999;43(suppl. C):55-59. (Pubitemid 29271929)
16. Bauernfeind A. Pharmacodynamics of levofloxacin and ofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 1999;43(suppl. C):77-82. (Pubitemid 29271933)
17. Miller D, Alfonso EC. Comparative in vitro activity of levofloxacin, ofloxacin, and ciprofloxacin against ocular streptococcal isolates. Cornea. 2004;23:289-293. (Pubitemid 38401906)
18. Fisher LM, Heaton VJ. Dual activity of fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother. 2003;51:463-464.
19. Sanders CC. Review of preclinical studies with ofloxacin. Clin Infect Dis. 1992;14: 526-538.
20. Wiseman LR, Balfour JA. Ciprofloxacin. A review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging. 1994;4:145-173.
21. Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA. 1995;92:11801-11805. (Pubitemid 26014932)
22. Breines DM, Ouabdesselam S, Ng EY, et al. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother. 1997;41:175-179. (Pubitemid 26428151)
23. Huelves L, Sevillano D, Martinez-Marin C, et al. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones. Int J Antimicrob Agents. 2006;27:294-299.
24. Pestova E, Millichap JJ, Noskin GA, Peterson LR. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother. 2000;45:583-590. (Pubitemid 30255636)
25. Ogawa GS, Weinstein AJ, Melendez RF, et al. Perioperative regimen in a large series of cataract surgeries with no cases of endophthalmitis. Proceedings of the ASCRS Symposium on Cataract, IOL and Refractive Surgery; April 27-May 2, 2007; San Diego, CA, USA.
26. Iquix® [package insert]. Jacksonville, FL: Vistakon Pharmaceuticals, Inc.; 2007.
27. Wagner RS, Abelson MB, Shapiro A, Torkildsen G. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch Ophthalmol. 2005;123:1282-1283. (Pubitemid 41316756)
28. Holland EJ, McCarthy M, Holland S. The ocular penetration of levofloxacin 1.5% and gatifloxacin 0.3% ophthalmic solutions in subjects undergoing corneal transplant surgery. Curr Med Res Opin. 2007;23:2955-2960.
29. Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection. 2001;29(suppl. 2):11-15. (Pubitemid 34001314)
30. Duggirala A, Joseph J, Sharma S, Nutheti R, Garg P, Das T. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison. Indian J Ophthalmol. 2007;55:15-19. (Pubitemid 46065927)
31. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466. (Pubitemid 34258055)
32. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505. (Pubitemid 37101247)
33. Miller D, Flynn PM, Scott IU, Alfonso EC, Flynn HW Jr. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol. 2006;124: 479-483.
34. Rhee MK, Kowalski RP, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 2004;138:226-230. (Pubitemid 39037426)
35. Miller JJ, Scott IU, Flynn HW Jr., Smiddy WE, Corey RP, Miller D. Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol. 2004;138:231-236. (Pubitemid 39037427)
36. Kowalski RP, Romanowski EG, Mah FS, Sasaki H, Fukuda M, Gordon YJ. A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinoloneresistant Staphylococcus aureus rabbit model. Jpn J Ophthalmol. 2008;52:211-216.
37. Thibodeaux BA, Dajcs JJ, Caballero AR, Marquart ME, Girgis DO, O'Callaghan RJ. Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. Curr Eye Res. 2004;28:337-342. (Pubitemid 38638808)
38. Tungsiripat T, Sarayba MA, Kaufman MB, et al. Fluoroquinolone therapy in multipledrug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model. Am J Ophthalmol. 2003;136:76-81. (Pubitemid 36794498)
39. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122:1-17. (Pubitemid 26230889)
40. Erratum in: Am J Ophthalmol. 1996;122:920.
41. Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol. 2003;87:834-838. (Pubitemid 36765243)
42. Wagoner MD, Al-Swailem SA, Sutphin JE, Zimmerman MB. Bacterial keratitis after penetrating keratoplasty: incidence, microbiological profile, graft survival, and visual outcome. Ophthalmology. 2007;114:1073-1079.
43. Vajpayee RB, Sharma N, Sinha R, Agarwal T, Singhvi A. Infectious keratitis following keratoplasty. Surv Ophthalmol. 2007;52:1-12. (Pubitemid 46038355)
44. Kim DH, Stark WJ, O'Brien TP, Dick JD. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients. Ophthalmology. 2005;112:1992-1996. (Pubitemid 41551929)
45. Holland EJ, Lane SS, Kim T, Raizman M, Dunn S. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea. 2008;27:314-319. (Pubitemid 351440866)
46. Chang D. Cataract clinical committee survey on antibiotic usage: TASS and endophthalmitis symposium. Proceedings of the ASCRS Symposium on Cataract, IOL and Refractive Surgery; April 27-May 2, 2007; San Diego, CA, USA.
47. Aliprandis E, Ciralsky J, Lai H, Herling I, Katz HR. Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. Cornea. 2005;24:201-205. (Pubitemid 40283832)
48. Caballero AR, Marquart ME, O'Callaghan RJ, Thibodeaux BA, Johnston KH, Dajcs JJ. Effectiveness of fluoroquinolones against Mycobacterium abscesses in vivo. Curr Eye Res. 2006;31:23-29. (Pubitemid 43155541)
49. Babayan Sosa A, Epstein SP, Asbell PA. Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells. Cornea. 2008;27:930-934.